Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tucidinostat + Tislelizumab in 1L PD-L1+ Advanced NSCLC
NCT05519865Phase 2Completed
- Sponsor
- Akeso, Inc.
- Start
- Oct 2022
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tucidinostat in non-small cell lung cancer (NSCLC), sponsored by Akeso, Inc.. Started Oct 2022; status: completed.
02
Drugs
tucidinostat
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05519865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05519865.